http://www.lamontanita.org/January08Newsletter_000pdf.html
Life sciences and technology investoSafeguard (NYSE:SFE) said the gain and an increaser in shareholders’ equity will be recognized in the currenrt quarter ending June 30. A privatre placement with reduced Safeguard’s share in Clarient from about 50 percent to about 47 Safeguard President and CEOPeter J. Boni said the deal “noyt only strengthened our balance sheer andfinancial flexibility, but the value of Safeguard’s ongoin stake in Clarient can now be more readily understoox by the investment community.” Safeguard said the markef value of its remaining holdings is about $123 million as of Wednesday.
Clarientt provides anatomic pathology and molecular testinfg servicesto pathologists, oncologists and the pharmaceutica l industry. It’s based in Aliso Calif.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment